Glaxosmithkline Regulatory News (GSK)

Outcome and Vesting Level

Portion of the Award

Measure and Outcome

% of maximum

% of award

30%

Total Shareholder Return - For the three-year period the Company's Total Shareholder Return ranked 5th, against a comparator group of 10 global pharmaceutical companies including GSK.

40%

12%

20%

Total Sales - For the three-year period, the Company achieved sales across our marketed products for the measure of £86.15bn, which is above the level of £80.29bn required for 100% vesting. The threshold vesting level was £75.71bn. 

100%

20%

20%

Total Profit - For the three-year period, the Company achieved £24.2bn, which is above the level of £23.62bn required for 100% vesting. The threshold vesting level was £22.27bn.

100%

20%

20%

Pipeline Progress - measure is equally weighted between:

- Pivotal trial starts

- Major regulatory approvals

100%

87.5%

10%

8.75%

10%

Trust: Environment - For the three-year period, all criteria for achieving our Trust priority and goal of having a Nature Net Positive and Climate Net Zero impact by 2030 have been met or exceeded in advance of the target date required to result in maximum vesting for this measure. 

100%

10%

Total vesting for 2022 award

Lapsed

80.75

19.25

80.75%

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan. These shares are now subject to a two-year hold. 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

420,177

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Diana Conrad

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

88,027

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Diana Conrad

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2531

47,121

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

143,381

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2531

67,390

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

50,221

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2531

23,604

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Luke Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

208,808

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Luke Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2531

14,763

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Shobie Ramakrishnan

b)

Position/status

Chief Digital and Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

The number of ADSs vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$0.00

47,681

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Shobie Ramakrishnan

b)

Position/status

Chief Digital and Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

The sale of ADSs to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$36.6355

25,705

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President, Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

153,657

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President, Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2531

72,219

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

135,261

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2531

63,573

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Phil Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

70,869

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Phil Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2531

33,309

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, GSK Global Health

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

133,405

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, GSK Global Health

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2531

62,701

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Tony Wood

b)

Position/status

Chief Scientific Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

97,444

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Tony Wood

b)

Position/status

Chief Scientific Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2531

45,799

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

10,755

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2531

5,055

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-02-18

f)

Place of the transaction

London Stock Exchange (XLON)